Clinical Trials

LymphoidOther hematologic neoplasm

26 enrolled

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07628582 2026-06-05

A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

48 enrolled

Recurrence

NCT07628894 2026-06-05

Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy

8 enrolled

Dermatologic

Melanoma

NCT07629089 2026-06-05

VALIENT

Brain Neoplasms, Glioma

NCT07631013 2026-06-05

Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

36 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT07443137 2026-06-04

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms, Cholangiocarcinoma

NCT07489287 2026-06-03

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Gynecologic

Ovarian Neoplasms

NCT07422896 2026-06-02

Bvax

25 enrolled

Glioblastoma

NCT07619599 2026-06-02

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

6 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07617363 2026-06-01

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

27 enrolled

Leukemia, Myeloid, Acute

NCT07614282 2026-05-29

Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia

28 enrolled

Infections, Epstein-Barr Virus Infections

NCT07347418 2026-05-28

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

MyeloidOther hematologic neoplasm

23 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07511426 2026-05-28

U96-CAR-T-Cells For R/R B-ALL

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, B-Cell

NCT07610707 2026-05-28

YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases

10 enrolled

Colorectal Cancer With Liver Metastatic

NCT07611370 2026-05-28

Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers

12 enrolled

Graft vs Host Disease

NCT07608627 2026-05-27

64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer

15 enrolled

Pancreatic Neoplasms

NCT06946680 2026-05-22

Peds IMPACT

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Glioblastoma, Glioma

NCT07478848 2026-05-22

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

14 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07495293 2026-05-22

Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer

Genitourinary

Prostatic Neoplasms

NCT07603596 2026-05-22

Opioid-free Anesthesia and Postoperative Delirium

174 enrolled

Emergence Delirium, Digestive System Neoplasms

NCT05976555 2026-05-20

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Plasma cell

Multiple Myeloma

NCT07549464 2026-05-20

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

12 enrolled

Leukemia, Myeloid, Acute

NCT07014878 2026-05-18

A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors

GastrointestinalThoracic

Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Neoplasms, Proteinuria

NCT07316686 2026-05-18

Lutécio

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07594067 2026-05-18

TCR1188-ABC Cells in KRAS-mutated Cancers

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Cholangiocarcinoma

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Adenocarcinoma Of Esophagus

NCT07411586 2026-05-15

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT07487168 2026-05-15

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Diseases, Peritoneal Neoplasms, Colorectal Neoplasms

NCT07590583 2026-05-15

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial

Breast

Advanced Hormone Receptor-Positive Breast Carcinoma

NCT07451054 2026-05-14

CD45BE-HSPC + CART-45 Cells

42 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT07587827 2026-05-14

ODI-2001-01

77 enrolled

Pancreatic Neoplasms, Colorectal Neoplasms

NCT07582822 2026-05-13

JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

60 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07583303 2026-05-13

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

19 enrolled

Leukemia, Myeloid, Acute

NCT07583654 2026-05-13

Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors

Tumor-Agnostic

Neoplasm Metastasis

NCT07583914 2026-05-13

Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors

9 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis

NCT07579208 2026-05-12

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

36 enrolled

Glioblastoma

NCT07580261 2026-05-12

YMN-A02 for Advanced Primary Hepatocellular Carcinoma.

10 enrolled

Carcinoma, Hepatocellular

NCT07582003 2026-05-12

A Phase I Trial of S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas

Adenoma, Disease, Colorectal Neoplasms

NCT07562815 2026-05-11

Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors

9 enrolled

Tumor-Agnostic

Neoplasms

NCT06233331 2026-05-08

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

9 enrolled

Gynecologic

Squamous Intraepithelial Lesions, Acquired Immunodeficiency Syndrome

NCT07444632 2026-05-08

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

60 enrolled

Lymphoid

Hodgkin Disease

NCT07279116 2026-05-07

ABY-029 Head & Neck Trial

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Breast

Triple Negative Breast Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07444606 2026-05-06

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

50 enrolled

Dermatologic

Melanoma

NCT07569263 2026-05-06

IMPACT MET

12 enrolled

Brain Neoplasms

NCT07283640 2026-05-05

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia